Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Operating Expenses: 2016-2025

Historic Operating Expenses for Summit Therapeutics (SMMT) over the last 5 years, with Sep 2025 value amounting to $234.2 million.

  • Summit Therapeutics' Operating Expenses rose 301.20% to $234.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $935.4 million, marking a year-over-year increase of 375.38%. This contributed to the annual value of $226.3 million for FY2024, which is 62.94% down from last year.
  • According to the latest figures from Q3 2025, Summit Therapeutics' Operating Expenses is $234.2 million, which was down 58.80% from $568.4 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Operating Expenses ranged from a high of $568.4 million in Q2 2025 and a low of $20.8 million during Q3 2023.
  • For the 3-year period, Summit Therapeutics' Operating Expenses averaged around $128.1 million, with its median value being $59.6 million (2024).
  • Its Operating Expenses has fluctuated over the past 5 years, first dropped by 8.24% in 2023, then spiked by 853.48% in 2025.
  • Summit Therapeutics' Operating Expenses (Quarterly) stood at $21.4 million in 2022, then soared by 69.79% to $36.4 million in 2023, then spiked by 81.17% to $65.9 million in 2024, then spiked by 301.20% to $234.2 million in 2025.
  • Its last three reported values are $234.2 million in Q3 2025, $568.4 million for Q2 2025, and $66.9 million during Q1 2025.